Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
European Journal of Endocrinology|February 13, 2026
Biological targets and therapeutic strategies in the treatment of non-functioning Pituitary Tumours: state-of-the-artFederica Mangili, Donatella Treppiedi, Genesio Di Muro, et al.
Frontiers in Endocrinology|March 5, 2021
A Novel Mechanism Regulating Dopamine Receptor Type 2 Signal Transduction in Pituitary Tumoral Cells: The Role of cAMP/PKA-Induced Filamin A PhosphorylationFederica Mangili, Donatella Treppiedi, Rosa Catalano, et al.
Frontiers in Endocrinology|August 22, 2022
Dimerization of GPCRs: Novel insight into the role of FLNA and SSAs regulating SST2 and SST5 homo- and hetero-dimer formationDonatella Treppiedi, Giusy Marra, Genesio Di Muro, et al.
Frontiers in Endocrinology|October 24, 2025
Potential antitumoral effects of SRPK1 inhibition through modulation of VEGF splicing in pituitary somatotroph tumoral cellsDonatella Treppiedi, Sonia Di Bari, Federica Mangili, et al.
Frontiers in Endocrinology|June 17, 2022
TMPRSS2 Expression and Activity Modulation by Sex-Related Hormones in Lung Calu-3 Cells: Impact on Gender-Specific SARS-CoV-2 InfectionDonatella Treppiedi, Giusy Marra, Genesio Di Muro, et al.
Endocrine-Related Cancer|June 19, 2026
Characterization of SF3B1 role in prolactin-secreting pituitary tumorsFederica Mangili, Anna Maria Barbieri, Genesio Di Muro, et al.
Molecular and Cellular Endocrinology|January 11, 2021
Filamin A is required for somatostatin receptor type 5 expression and pasireotide-mediated signaling in pituitary corticotroph tumor cellsDonatella Treppiedi, Genesio Di Muro, Federica Mangili, et al.
Endocrine-Related Cancer|June 4, 2021
USP8 inhibitor RA-9 reduces ACTH release and cell growth in tumor corticotrophsDonatella Treppiedi, Genesio Di Muro, Giusy Marra, et al.
Frontiers in Endocrinology|June 20, 2022
DRD2 Agonist Cabergoline Abolished the Escape Mechanism Induced by mTOR Inhibitor Everolimus in Tumoral Pituitary CellsFederica Mangili, Emanuela Esposito, Donatella Treppiedi, et al.
Cancers|June 28, 2023
A β-Arrestin 2-Biased Dopamine Receptor Type 2 (DRD2) Agonist Is More Efficacious Than Cabergoline in Reducing Cell Proliferation in PRL-Secreting but Not in Non-Functioning Pituitary Tumor CellsGenesio Di Muro, Federica Mangili, Emanuela Esposito, et al.
Pageof 2